For in vitro diagnostic use. Others BNZ2 IVD BNZ2 CPS_000052 ONLINE DAT Benzodiazepines II 04939417190 BENZ2, 200T, cobas c BNZ2 04015630999347 Reagents, kits 200 tests cobas c 311/501/502 true 04780248190 COBAS INTEGRA BENZ II 200 BNZ2 04015630998609 Reagents, kits 200 tests COBAS INTEGRA 400 Plus true 08056927190 BENZ2, 850T, cobas c pack green BNZ2 07613336121054 Reagents, kits 850 tests cobas c 303/503/703 true 06334415190 BNZ2, 100T, cobas c 701/702 BNZ2 04015630930319 Reagents, kits 100 tests cobas c 701/702 true 0204939417190c501 BNZ2 ONLINE DAT Benzodiazepines II en 2 FF00000006AC8F0E FF000000060EBB0E 04939417190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useBenzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine on cobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS), or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS).Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 04939417500 BNZ2 ONLINE DAT Benzodiazepines II en 10 FF00000006AC030E FF0000000058590E 04939417190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineBenzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine on cobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/massspectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. Application in serum and plasma**not available in all countriesONLINE DAT Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative detection of benzodiazepines in human serum and plasma on cobas c systems at a cutoff concentration of 200 ng/mL. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1704939417190c501sp BNZ2 ONLINE DAT Benzodiazepines II en 4 FF000000045F1E0E FF00000001D5140E 04939417190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useONLINE DAT Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative detection of benzodiazepines in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 200 ng/mL. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0108056927190c503 BNZ2 ONLINE DAT Benzodiazepines II en 4 FF000000059B620E FF000000053F420E 08056927190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine on cobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1708056927190c503sp BNZ2 ONLINE DAT Benzodiazepines II en 4 FF000000053F8B0E FF000000053F8B0E 08056927190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useONLINE DAT Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative detection of benzodiazepines in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 200 ng/mL. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1708056927190c503sp BNZ2 ONLINE DAT Benzodiazepines II en 3 FF000000045F240E FF0000000377BE0E 08056927190 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useONLINE DAT Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative detection of benzodiazepines in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 200 ng/mL. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0108056927190c503 BNZ2 ONLINE DAT Benzodiazepines II en 2 FF000000045EBA0E FF0000000381900E 08056927190 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine on Roche/Hitachi cobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 06334415500 BNZ2 ONLINE DAT Benzodiazepines II en 6 FF00000006AC020E FF00000000585D0E 06334415190 2492 cobas c 702 310 cobas c 701 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useBenzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine oncobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Benzodiazepines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.,LREFSalamone SJ, ed. Benzodiazepines and GHB: Detection and Pharmacology. Totowa, NJ: Humana Press 2001. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en